CALGARY and SAN DIEGO, CA, Dec. 27,
2017 /PRNewswire/ - Oncolytics Biotech® Inc.
(TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech
company developing REOLYSIN®, also known as pelareorep,
an intravenously delivered immuno-oncolytic virus that activates
the innate and adaptive immune systems to turn 'cold' tumors 'hot',
today announced that data from REO 024 will be presented at the
2018 Gastrointestinal Cancers Symposium sponsored by ASCO,
January 18 – 20, 2018, in San
Francisco. The poster presentation by Dr. Devalingam
Mahalingam, M.D. Ph.D., Associate Professor of Medicine (Hematology
and Oncology) at the Feinberg School of
Medicine, Northwestern University, will present clinical
data evaluating intravenous administration of pelareorep in
combination with pembrolizumab (KEYTRUDA®) and
chemotherapy in patients with advanced or metastatic pancreatic
adenocarcinoma.
"I'm thrilled that Dr. Mahalingam will have the opportunity to
present data from the REO 024 study combining pelareorep with
Merck's Keytruda and chemotherapy," said Dr. Matt Coffey, President and CEO of Oncolytics
Biotech. "While our focus remains on metastatic breast cancer, we
continue to be very interested in the potential to treat pancreatic
cancer patients. Our NCI-8601 study demonstrated an increase
in landmark survival at two years in pancreatic patients from nine
percent to twenty percent, when comparing pelareorep plus
carboplatin to carboplatin alone. Our REO 017 study improved
overall two-year survival in pancreatic patients from historical
measures of four to five percent to twenty-four percent, when
comparing pelareorep plus gemcitabine to gemcitabine alone. We
believe there is an obvious therapeutic effect in pancreatic cancer
and look forward to this presentation in January."
|
Abstract number:
|
283
|
|
Title:
|
A study of
pelareorep in combination with pembrolizumab and chemotherapy in
patients (pts) with relapsed metastatic adenocarcinoma of the
pancreas (MAP)
|
|
Poster Session:
|
Session B: Cancers of
the Pancreas, Small Bowel, and Hepatobiliary Tract
|
|
Date/Time:
|
January 19, 11:30
AM-1:00 PM; 5:30 PM-6:30
|
|
|
About REOLYSIN/Pelareorep
REOLYSIN, also known as
pelareorep, is a non-pathogenic, proprietary isolate of the
unmodified reovirus: a first-in-class intravenously delivered
immuno-oncolytic virus for the treatment of solid tumors and
hematological malignancies. The compound induces selective tumor
lysis and promotes an inflamed tumor phenotype through innate and
adaptive immune responses to treat a variety of cancers.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, also known as
pelareorep, an intravenously delivered immuno-oncolytic virus. The
compound induces selective tumor lysis and promotes an inflamed
tumor phenotype – turning 'cold' tumors 'hot' – through innate and
adaptive immune responses to treat a variety of cancers.
Oncolytics' clinical development program emphasizes three pillars:
chemotherapy combinations to trigger selective tumor lysis;
immuno-therapy combinations to produce adaptive immune responses;
and immune modulator (IMiD) combinations to facilitate innate
immune responses. Oncolytics is currently planning its first
registration study in metastatic breast cancer, as well as studies
in combination with checkpoint inhibitors and targeted and IMiD
therapies in solid and hematological malignancies. For further
information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended and forward-looking information under applicable
Canadian securities laws (such forward-looking statements and
forward-looking information are collectively referred to herein as
"forward-looking statements"). Forward-looking statements,
including the Company's belief as to the potential and mode of
action of REOLYSIN, also known as pelareorep, as a
cancer therapeutic; the Corporation's proposed use of
pelareorep in combination with pembrolizumab (KEYTRUDA®) and
chemotherapy in patients with advanced or metastatic pancreatic
adenocarcinoma; the timing and content of the presentation of
clinical data evaluating intravenous administration of pelareorep
in combination with pembrolizumab (KEYTRUDA®) and chemotherapy in
patients with advanced or metastatic pancreatic adenocarcinoma
; and other statements related to anticipated developments in
the Company's business and technologies involve known and unknown
risks and uncertainties, which could cause the Company's actual
results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development projects, the efficacy of pelareorep as a cancer
treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
pelareorep, uncertainties related to the research and development
of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.